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This study examined the effect of an orally active thromboxane (TXAr) synthetase inhibitor (TSI) on 
the patency, TXA, production, and platelet accumulation of reversed autogenous vein grafts. Ten dogs 
received TSI (U-63557A) 10 m&g po q8 hr for 6 weeks, beginning 24 hr prior to surgery, while 15 
control dogs were untreated One jugular vein was harvested and stored in 37°C saline for 1 hr to induce 
mild endothelial injury (siored). Normal and stored jugular vein grafts (8 cm) were then implanted in 
opposite femoral arteries while 3-cm segments of the same veins were implanted in the carotid arteries. 
Femoral graft flow was restricted with a 5 Fr distal arterial stenosis and patency determined by arteriography 
at 1,2,4, and 6 weeks. Vein graft endothelial surface TXBt production was measured by RIA at graft 
implantation and in carotid grafts harvested at 1 week. “‘In-labeled platelets were given iv 24 hr prior 
to carotid graft harvest to determine graft-platelet deposition. TSI treatment improved early (1 week) 
femoral vein graft patency from 63 to 89% (P c 0.05), a trend that persisted for 6 weeks. Warm saline 
storage reduced l-week graft patency from 83 to 63% (P < 0.05), a difference that decreased with time. 
TSI treatment resulted in a marked decrease in TXBr production, but was not associated with decreased 
“‘In-labeled platelet deposition in carotid vein grafts. Warm saline storage increased graft-platelet de- 
position which was predominant at the arterial anastomoses. TSI treatment may improve early vein 
graft patency during the transient period of endothelial injury. 8 1986 Academic PW, IUC. 
INTRODUCTION study was designed to test the ability of a new 
Aspirin is frequently used as an antiplatelet TSI, U-63557A [24], to enhance the patency 
agent in an attempt to improve the patency rate of autogenous vein grafts in the canine 
rate of small diameter vascular grafts. Such femoral artery circulation. The in vivo pro- 
cyclooxygenase inhibitors, however, have the duction of TXBz (the stable metabolite of 
theoretical disadvantage of inhibiting prosta- TXAz) and platelet accumulation on vein graft 
cyclin (PGIz) production in addition to surfaces were measured to correlate with the 
thromboxane A2 (TXAz) synthesis. This crit- effect of U-63557A on graft patency. 
icism has stimulated the development of se- 
lective thromboxane synthetase inhibitors METHODS 
(TSIs) which may increase PGIz production 
by redirecting endoperoxide precursors that 
Graft patency determination. Twenty-five 
accumulate during TXAz inhibition [ll]. 
adult mongrel dogs of both sexes (18-30 kg) 
Since autogenous vein grafts retain the ability 
were divided into control (n = 15) and treat- 
to synthesize PGIl [6], we hypothesized that 
ment (n = 10) groups. Treatment dogs re- 
TSI treatment would be more beneficial for 
ceived U-63557A [sodium 5-(3’-pyridinyl- 
these grafts than for prosthetic grafts. This 
methyl)benzofuran-2-carboxylate 1, an orally 
active TSI, 10 mg/kg po q8 hr beginning 24 
’ To whom reprint requests should be addressed: De- hr prior to surgery and continuing for the 6- 
partment of Surgery, Dartmouth College, Hanover, New week duration of study. Control dogs received 
Hampshire 03756. no treatment. After iv thiamylal induction, 
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dogs were anesthetized with halothane, nitrous 
oxide, and oxygen inhalation for graft im- 
plantation. Using sterile technique, the fem- 
oral and carotid arteries and external jugular 
veins were exposed bilaterally. Both jugular 
veins were harvested to provide an 8-cm seg- 
ment for superficial femoral artery (SFA) im- 
plantation in all dogs; a 3-cm segment for 
common carotid artery implantation in six 
treated and eight control dogs; and a 2-cm 
segment for baseline TXBz assay in all dogs. 
One of the jugular veins was removed for im- 
mediate implantation without storage, disten- 
tion, or irrigation, while the contralateral jug- 
ular vein was placed in 37°C normal saline 
storage for 1 hr in an attempt to induce en- 
dothelial damage. Vein grafts placed in the 
femoral location were reversed and anasto- 
mosed in an end-to-side fashion using contin- 
uous 6-O polypropylene suture with spatula- 
tion of the anastomoses, from the proximal 
SFA, immediately distal to the profunda 
branch, to a point in the SFA 8 cm distally. 
A 5 Fr ligature was placed around the distal 
SFA in order to reproducibly restrict graft 
outflow. The mid portion of the SFA was li- 
gated to completely divert blood flow through 
the vein graft. Vein grafts placed in the com- 
mon carotid arteries were reversed and anas- 
tomosed in an end-to-end fashion using con- 
tinuous 6-O polypropylene suture. Femoral 
and carotid vein grafts were simultaneously 
implanted by two operating teams to ensure 
equivalent graft treatment and storage time. 
The jugular vein removed for immediate use 
(normal vein) was implanted on one side in 
both the carotid and femoral locations, while 
the jugular vein selected for I-hr warm saline 
storage (stored vein) was implanted into the 
contralateral carotid and femoral artery lo- 
cations. 
A midline, lower abdominal incision was 
used to expose the middle sacral artery. An 
INFUSAID injection port was implanted in a 
subcutaneous pocket in the lower abdomen 
and its Silastic catheter placed just inside the 
infrarenal aorta via the middle sacral artery 
for subsequent arteriography. The surgical in- 
cisions were closed and the dogs recovered 
from anesthesia. Normal saline ( 1 - 1.5 1 iv) was 
administered during the 3-hr operative pro- 
cedure, and penicillin-G plus streptomycin 
were administered im preoperatively and on 
Postoperative Days 1 and 2. 
Arteriograms were obtained under brief 
thiamylal sodium anesthesia at 24 hr and at 
1, 2, 4, and 6 weeks postoperatively. Reno- 
grafin-76 (20 ml) was injected into the infrare- 
nal aorta via the subcutaneous injection port 
and a single timed X-ray exposure was made 
to visualize the femoral artery grafts. 
Graft platelet deposition. The subset of dogs 
that received carotid vein grafts underwent in- 
dium-1 11 oxine platelet labeling on Postop- 
erative Day 6. Platelet labeling was performed 
using a modification of the technique of 
Thakur et al. [23]. Venous blood was drawn 
through a large bore needle into plastic sy- 
ringes containing two different anticoagulants 
(36 ml blood4 ml acid citrate dextrose (ACD); 
18 ml blood2 ml 3.8% sodium citrate). After 
centrifugation of these separate samples at 
2008 for 10 min, platelet-rich plasma (PRP) 
and platelet-poor plasma (PPP) were isolated. 
Both ACD and sodium citrate-prepared PRP 
were then centrifuged at 1OOg for 10 min. 
Traces of ACD plasma in the platelet button 
were eliminated by twice layering and remov- 
ing 2 ml of modified Tyrodes solution (MTS) 
[23] at 37°C. Platelet pellets were then sus- 
pended in 4 ml MTS at 37°C and 500 mCi 
(0.5 ml) of “‘In oxine (Amersham, saline so- 
lution) was added dropwise to the platelet sus- 
pension. Platelets were then incubated at 37°C 
for 10 min, and 4 ml of ACD-prepared PPP 
was added prior to 7-min centrifugation at 
1 OOOg to remove any unbound oxine. The la- 
beled platelets were finally resuspended in 4 
ml of sodium citrate-prepared PPP for iv rein- 
jection into the animal. 
One day later, the dogs were reanesthetized 
(thiamylal sodium), the neck incisions reex- 
plored, and the carotid vein grafts harvested 
to include a l-cm segment of proximal and 
distal native carotid artery. After removal, the 
graft segments and adjacent carotid artery were 
gently flushed with normal saline to remove 
any contained blood. The grafts were then di- 
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vided into five segments, 1 cm in length, con- 
sisting of proximal and distal native carotid 
artery, proximal and distal anastomoses, and 
central vein graft. Each sample was weighed 
and subsequently counted for ’ ’ ’ In activity in 
a gamma well counter. A sample of blood was 
removed at the time of carotid graft harvest 
and also counted to determine the “I In ac- 
tivity of circulating platelets. Since graft and 
artery diameters were uniform in these dogs, 
small variations in the length of the counted 
graft and artery segments were normalized by 
dividing the counts per segment by the seg- 
ment weight. Platelet deposition was expressed 
as the ratio of the “‘In counts per gram of 
graft (artery) segment divided by the counts 
per 100 ~1 of circulating blood. 
Thromboxane production. Luminal vein 
graft TXBz production was measured using a 
technique suggested by Eldor et al. [ 121. The 
segment of vein to be analyzed was incised 
longitudinally to expose the endothelial sur- 
face, which was gently but thoroughly irrigated 
with Tris buffer (pH 7.4). The vein segment 
was then clamped in a plastic template which 
exposed a 0.79~cm* endothelial surface area 
to a 2-cm-deep circular well which was filled 
with 1 ml Tris buffer at 37°C. The vein graft 
was incubated in this template for 30 min at 
37”C, after which the buffer was removed and 
frozen for subsequent TXB2 radioimmunoas- 
say [ 131. Vein graft TXB2 production was 
measured at the time of graft implantation 
from both immediately implanted and warm 
saline-stored graft segments, as well as from 
vein grafts harvested after 1 week of carotid 
implantation. The central portion of the ca- 
rotid vein graft was used for this determination 
prior to the determination of its “‘In activity. 
Statistical analysis. Vein graft patency was 
analyzed by product moment actuarial tech- 
nique with significant differences determined 
by the Wilcoxon test. Patency at individual 
time points for TSI-treated and control dogs 
was tested by the Fisher exact test for inde- 
pendent samples, while differences between 
immediately implanted and warm saline- 
stored grafts were tested by the McNemar test 
for paired data [9]. TXB2 production and ” ‘In 
platelet deposition were compared between 
treatment groups by the Mann-Whitney test 
and within treatment groups by the Wilcoxon 
sign ranks test (all two-tail analyses) [9]. Cor- 
relation between graft patency, TXB2 produc- 
tion, and platelet deposition was measured by 
the Spearman rank correlation coefficient. 
RESULTS 
In this canine model, autogenous jugular 
vein grafts placed in the femoral artery location 
demonstrated 6-week cumulative patency 
rates of 53 to 70%. Most graft occlusions oc- 
curred during the first 2 weeks of implantation, 
with only 2 of 50 grafts occluding between 2 
and 6 weeks (Fig. 1). TSI treatment appeared 
to improve the patency of both normal and 
warm saline stored vein grafts when compared 
with untreated control dogs, although actuarial 
analysis of these survival curves did not dem- 
onstrate statistical significance (Wilcoxon test). 
The effect of TSI was most apparent 1 week 
after graft implantation when normal vein 
grafts in control dogs demonstrated a 27% 
lower patency than in TSI-treated dogs (P 
= 0.13, Fisher exact test, Table 1). This nearly 
significant difference also existed for saline 
stored grafts, which had a 27% lower l-week 
patency in control dogs compared with TSI- 
treated dogs (P = 0.20, Fisher exact test, Table 
1). In addition to the effect of drug treatment 
/_1 
Time (weeks) 
FIG. 1. Femoral artery autogenous vein graft patency 
in 15 control and 10 thromboxane synthetase inhibitor 
(TSI)-treated dogs (means + SEM). Normal and warm 
saline-stored vein grafts were placed in contralateral sides 
in each animal. 
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TABLE 1 
FEMORAL ARTERY AUT~GENOUS VEIN GRAFT PATENCY (w) 
1 week 
Normal vein Stored vein 






P = 0.19* 
TSI treated 100% 80% 
l- P = 0.15** --I 
* Fisher exact test for independent samples (two tailed). 
** McNemar test for paired data (two tailed). 
6weeks 







on graft patency, warm saline storage reduced 
l-week graft patency by 20% in both TSI- 
treated and control dogs. These differences, 
which approached statistical significance at 1 
Graft and treatment subgroups were com- 
bined to evaluate the effect of TSI treatment 
week, were nearly eliminated by 6 weeks, when 
on both normal and saline-stored vein grafts 
(n = 30 control, n = 20 treatment), as well as 
normal and saline-stored veins had compa- 
the effect of warm saline storage on both con- 
trol and TSI treated dogs (n = 25 normal, n 
rable patency rates (Table 1). 
= 25 stored vein grafts). TSI treatment im- 
proved early (1 week) vein graft patency from 
63 to 89% (Fig. 2, P < 0.05, Fisher exact test). 
Although this effect persisted for 6 weeks, the 
difference in overall survival curves only ap- 
proached statistical significance (P = 0.21, 
Wilcoxon test). Warm saline storage reduced 
l-week graft patency from 83 to 63% (Fig. 3, 
P < 0.05, McNemar test). This difference 
subsequently decreased with time, however, 
so that no difference existed between normal 
and saline-stored grafts at 6 weeks (P = 0.3 1, 
Wilcoxon test). 
Vein graft TXB2 production was three to 
seven times lower in TSI-treated dogs than in 
control dogs when assayed at implantation and 
at 1 week postoperatively (Table 2). These re- 
ductions were highly significant for both nor- 
mal and warm saline-stored grafts. TXB2 pro- 
duction increased three- to sevenfold in all vein 
grafts removed at 1 week compared with the 
same grafts at implantation. There was no sig- 
nificant difference in TXB2 production, how- 
’ ’ ‘In-labeled platelet deposition occurred 
predominantly at the proximal and distal ca- 
ever, between normal and saline-stored vein 
rotid vein graft anastomoses. There was no 
significant difference in platelet deposition be- 
grafts at implantation or at 1 week postoper- 
tween the proximal and distal carotid artery 
segments and the midportion of normal jug- 
ular vein grafts in control dogs (Table 3). Sig- 
atively (Table 2). 





E f ““;:;y , , , 
0 I 2 3 4 5 6 
Time (weeks) 
FIG. 2. Patency of all femoral vein grafts (both normal 
and saline stored) in control versus thromboxane synthe- 
tase inhibitor (TSI)-treated dogs (means + SEM). At 1 
week, *P < 0.05, Fisher exact test. 
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. STORED VEIN GRAFTS 
I 1 I I I I 
0 I 2 3 4 5 6 
Time (weeks) 
FIG. 3. Patency of normal versus warm saline-stored 
autogenous vein grafts in the femoral artery position of 
both control and TSI-treated dogs (means f  SEM). At 1 
week, *P < 0.05, McNemar test. 
cur at both anastomoses. Platelet deposition 
was two to four times greater in saline-stored 
vein grafts in the same control dogs, at both 
the anastomoses and the vein grail itself (Table 
3). Dogs treated with TSI also demonstrated 
increased platelet deposition at the anasto- 
moses, but also in the vein graft itself, when 
compared with proximal or distal artery seg- 
ments. This enhanced platelet accumulation 
in normal vein grafts of TSI-treated dogs was 
significantly greater than the mimimal depo- 
sition seen in control dogs (P < 0.02, Mann- 
Whitney test). No other significant differences 
in platelet deposition existed between control 
and TSI treated animals. As with control dogs, 
saline-stored vein grafts demonstrated in- 
creased platelet deposition in both the graft 
and the anastomoses when compared with 
proximal or distal native artery (Table 3). 
There was no correlation (rS < 0.2) between 
platelet deposition (vein graft or anastomoses) 
and TXB2 production at the time of carotid 
vein graft harvest. Furthermore, there was no 
correlation between vein graft TXB2 produc- 
tion or platelet deposition and l- or 6-week 
patency of comparably treated femoral artery 
grafts in the same animals. 
DISCUSSION 
In contrast to aspirin and other cyclooxy- 
genase inhibitors, selective inhibition of TXA2 
synthetase has the theoretical advantage of 
preserving or increasing PGIl production. Ac- 
cumulated endoperoxides resulting from 
TXA2 inhibition appear to be redirected to 
enhance PGI* synthesis when PGIz synthetase 
is available [8, 10, 1 I]. Despite this potential 
advantage, TSIs do not inhibit in vitro platelet 
aggregation as consistently as aspirin [ 81. This 
may be due to the proaggregatory activity of 
certain endoperoxide intermediates that do 
not accumulate after cyclooxygenase inhibi- 
tion [lo]. These considerations suggest that 
selective TXA2 inhibition would have maxi- 
mum advantage over cyclooxygenase inhibi- 
tion in conjunction with autogenous tissue 
that is capable of PG12 generation. 
Despite these theoretical objections, aspirin 
TABLE 2 
THROMEOXANE B2 PRODU~ION (rig/O.79 cm2 VEIN SURFACE/~~ min) 
Normal vein grafts” Stored vein grafts’ 
Time Control TSI treated P valueb Control TSI treated P value” 
Implantation 431 + 58 129 + 57 <0.002 
! 






1 week postoperative 
I 
2727 I? 1065 
I 
378 + 86 
I 
co.003 2266 f  545 555 + 141 <O.Ol 
Note. Values are means + SEM. 
* P i 0.03, Implantation vs 1 week, Wilcoxon sign ranks test. 
LI Normal vs stored vein grafts, no significant differences, Wilcoxon sign ranks test. 
b Control vs TSI-treated dogs, Mann-Whitney test. 
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TABLE 3 












5.8 _+ 1.0 -***~***~J 7 k 1 6 **13.9 + 2.9 
; 
.I . I. . 
5.1 + 1.1 











5.8 f  0.8 **16.3 f  4.1 
I I 
**#lo.2 Ii 1.0 **16.1 f  4.1 5.5 + 1.2 






8.7 f  2.1 “22.7 f  4.4 *18.8 + 3.6 *27.3 + 6.3 1.6 +- 2.4 
InsInsA 
* P < 0.10, **P < 0.05, ***P < 0.025, Wilcoxon sign-ranks test (two tail). #P < 0.02, control vs TSI-treated dogs 
for normal vein grafts, Mann-Whitney test. Other control vs treated dog comparisons all nonsignificant (P > 0.10). 
(often combined with dipyridamole) has im- 
proved aortocoronary vein graft patency in 
some clinical trials and has reduced vein graft 
anastomotic intimal fibroplasia in experimen- 
tal models [6, 201. In contrast, aspirin treat- 
ment in rabbit endothelial injury models in- 
hibited endothelial healing, enhanced platelet 
accumulation, and reduced PGIz production 
[3, 41. Treatment of injured rabbit endothe- 
lium with TSI, however, reduced platelet de- 
position and enhanced PG12 synthesis [ 10, 16, 
2 11. Furthermore, aspirin-dipyridamole did 
not increase the patency rate of lower extrem- 
ity autogenous vein grafts in humans [ 191. 
Since vein graft occlusion remains a significant 
clinical problem, the above considerations 
suggested our study of the effect of selective 
TXA2 inhibition on vein graft patency. 
Although TSI caused a marked reduction 
of TXB2 production in our study, its ability 
to improve vein graft patency was only mod- 
est. Furthermore, even though improved early 
graft patency was seen in TSI-treated dogs, no 
corresponding reduction in graft-platelet de- 
position was demonstrated. Since vein grafts 
do not accumulate sufficient ’ ’ ‘In-labeled 
platelets for external gamma camera imaging, 
it was necessary to remove vein grafts to mea- 
sure platelet deposition in a well counter. This 
prevented the measurement of graft patency 
and platelet deposition in the same graft and 
led to the use of carotid and femoral artery 
sites in our model. In retrospect, differences 
in anastomotic technique, graft length, and 
blood flow rate might have caused predictable 
differences in platelet deposition between 
femoral and carotid artery grafts. Although we 
did not measure graft flow rates, femoral out- 
flow stenosis almost certainly caused signifi- 
cantly lower graft blood flow in the femoral 
than in the carotid location. Since lower flow 
rates increase platelet graft deposition [7], 
measurement of platelet deposition in the 
femoral grafts themselves might have corre- 
lated better with early improved femoral graft 
patency in TSI-treated dogs. These results, 
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therefore, should not be interpreted as dis- 
proving a relationship between TSI effects on 
graft patency and a potential anti-platelet 
mechanism. 
Our finding of improved early vein graft 
patency after TSI treatment is supported by a 
recent report of Bergquist et al. [2]. These in- 
vestigators demonstrated that dazoxiben, an 
imidozole-derived TSI, improved the patency 
of human umbilical vein grafts after 4 hr of 
ex viva perfusion in sheep. Decreased platelet 
deposition and thrombus weight were asso- 
ciated with decreased TXB2 production. Da- 
zoxiben and other TSIs have also been shown 
to reduce platelet adhesion on endothelium 
damaged rabbit arteries and to reduce TXB2 
but increase PGIz production [ 10, 2 11. A sig- 
nificant effect of TSI treatment was not seen 
with Dacron grafts, however, where dazoxiben 
failed to reduce platelet deposition in an ex 
viva perfusion circuit or in baboon A-V shunts, 
despite reduced TXBz production [ 14, 171. 
These observations suggest that endogenous 
PG12 production, not present in prosthetic 
grafts, may be essential for TSI efficacy. This 
has been demonstrated in a canine coronary 
artery stenosis model in which effective TSI 
prevention of platelet aggregation was blocked 
by cyclooxygenase inhibition that prevented 
PG12 production [ 1, 151. U-63557A, the TSI 
used in this study, has been shown to signifi- 
cantly reduce TXBP production in dogs, mon- 
keys, and humans without tachyphylaxis after 
14 days of oral administration [ 151. A dose of 
10 mg/kg markedly reduced TXB2 production 
in dogs for 4 to 6 hr [24]. Recent experience 
in our laboratory suggests that a larger dose of 
U-63557A might have had more beneficial ef- 
fects in this study. 
Vein graft storage in 37°C saline was used 
in our study to produce a mild endothelial in- 
jury analogous to some clinical settings. 
LoGerfo et al. reported that such storage re- 
sulted in early endothelial disruption and 
platelet-leukocyte adhesion, with subsequent 
medial thickening [ 181. Although we did not 
examine these morphologic changes, warm 
saline storage was associated with reduced vein 
graft patency and increased platelet accumu- 
lation 1 week after implantation, during the 
time when endothelial injury exists, according 
to LoGerfo et al. Elimination of the saline 
storage effect on 4- to 6-week graft patency 
corresponds to the time course of endothelial 
healing after this degree of vein injury [ 181. 
The basis for increased TXB2 production after 
1 week of vein graft implantation was not spe- 
cifically investigated in this study. We specu- 
late that this increased production may have 
resulted from increased luminal accumulation 
of platelets, monocytes, and leukocytes during 
the first postoperative week that were not 
present when vein grafts were implanted. Al- 
though arteries and veins have been shown to 
synthesize TXA2 in addition to their more 
predominant PGIz production [22], electron 
microscopy of the vein graft luminal surface 
would be necessary to exclude a major TXA;! 
contribution from adherent blood elements. 
The use of femoral artery outflow stenosis 
to reduce autogenous vein graft patency re- 
sulted in a 6-week graft patency rate of 53 to 
58% in control dogs. Since no grafts occluded 
between 4 and 6 weeks, this appears to be a 
practical model to investigate vein graft pa- 
tency in a 4-week study in dogs. Such a tech- 
nique is necessary since unrestricted flow 
through canine autogenous vein grafts nearly 
always results in 100% long-term patency, 
making such an animal model impractical for 
a study with graft occlusion as the endpoint. 
Although it is generally accepted that plate- 
let-graft interaction is an important contrib- 
utor to arterial graft failure, it is equally clear 
that many factors influence early and late graft 
patency. Since we do not yet have data con- 
cerning the ability of aspirin or other cycloox- 
ygenase inhibitors to improve the patency of 
vein grafts in this particular animal model, it 
is difficult to judge the significance of the im- 
provement seen with TSI in this report. The 
ability of TSI to improve early vein graft pa- 
tency, during the period of maximal, but tran- 
sient endothelial injury and decreased PGIz 
production, however, might be important. 
These results should stimulate a comparison 
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of the chronic effects of both TSI and aspirin 
on graft patency and platelet deposition in an 
appropriate animal model. 
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